Compare Infosys Limited (INFY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Mesoblast Limited — how do they compare? Infosys Limited trades at $12.4 (market cap $50.32B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Infosys Limited is far larger — about 23.3× Mesoblast Limited's market cap, and Infosys Limited pays a 4.17% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| INFY | MESO | |
|---|---|---|
Market Cap | $50.32B | $2.16B |
Sector | Technology | Technology |
52-Week High | $20.22 | $20.96 |
52-Week Low | $10.49 | $12.88 |
Enterprise Value | $48.07B | $2.17B |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.53, up 1.38% today, with a bullish technical signal from moving averages. The company reported a Q1 2027 revenue miss but maintained strong operating margins of 21.1% and announced a CEO transition. Recent news highlights strategic AI collaborations, such as with Metsä Group and Sentara, driving digital transformation initiatives.
The outlook is mixed: robust profitability and AI growth offer upside, but lowered revenue guidance and competitive pressures pose risks. Analyst consensus is cautious with a $11.05 price target below the current price, suggesting limited near-term upside amid execution challenges.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
